false DEFA14C OSD Test Company #1 9876543210 9876543210 2021-04-01 2022-03-31 9876543210 2020-04-01 2021-03-31 9876543210 2019-04-01 2020-03-31 9876543210 2018-04-01 2019-03-31 9876543210 2017-04-01 2018-03-31 9876543210 pvp08:BockMember pvp08:AdjType1Member 2021-04-01 2022-03-31 9876543210 pvp08:BockMember pvp08:AdjType2Member 2021-04-01 2022-03-31 9876543210 pvp08:BockMember 2021-04-01 2022-03-31 9876543210 pvp08:GaleMember pvp08:AdjType1Member 2021-04-01 2022-03-31 9876543210 pvp08:MurphyMember pvp08:AdjType1Member 2021-04-01 2022-03-31 9876543210 pvp08:HoodMember pvp08:AdjType1Member 2021-04-01 2022-03-31 9876543210 pvp08:HoodMember pvp08:AdjType2Member 2021-04-01 2022-03-31 9876543210 pvp08:MurphyMember pvp08:AdjType2Member 2021-04-01 2022-03-31 9876543210 1 2021-04-01 2022-03-31 9876543210 ecd:PeoMember ecd:AggtChngPnsnValInSummryCompstnTblForAplblYrMember 2021-04-01 2022-03-31 9876543210 ecd:PeoMember ecd:PnsnAdjsSvcCstMember 2021-04-01 2022-03-31 9876543210 ecd:PeoMember ecd:PnsnAdjsPrrSvcCstMember 2021-04-01 2022-03-31 9876543210 ecd:PeoMember ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember 2021-04-01 2022-03-31 9876543210 ecd:PeoMember ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember 2021-04-01 2022-03-31 9876543210 ecd:PeoMember ecd:AggtChngPnsnValInSummryCompstnTblForAplblYrMember 2020-04-01 2021-03-31 9876543210 ecd:PeoMember ecd:PnsnAdjsSvcCstMember 2020-04-01 2021-03-31 9876543210 ecd:PeoMember ecd:PnsnAdjsPrrSvcCstMember 2020-04-01 2021-03-31 9876543210 ecd:PeoMember ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember 2020-04-01 2021-03-31 9876543210 ecd:PeoMember ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember 2020-04-01 2021-03-31 9876543210 ecd:PeoMember ecd:AggtChngPnsnValInSummryCompstnTblForAplblYrMember 2019-04-01 2020-03-31 9876543210 ecd:PeoMember ecd:PnsnAdjsSvcCstMember 2019-04-01 2020-03-31 9876543210 ecd:PeoMember ecd:PnsnAdjsPrrSvcCstMember 2019-04-01 2020-03-31 9876543210 ecd:PeoMember ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember 2019-04-01 2020-03-31 9876543210 ecd:PeoMember ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember 2019-04-01 2020-03-31 9876543210 ecd:NonPeoNeoMember ecd:AggtChngPnsnValInSummryCompstnTblForAplblYrMember 2021-04-01 2022-03-31 9876543210 ecd:NonPeoNeoMember ecd:PnsnAdjsSvcCstMember 2021-04-01 2022-03-31 9876543210 ecd:NonPeoNeoMember ecd:PnsnAdjsPrrSvcCstMember 2021-04-01 2022-03-31 9876543210 ecd:NonPeoNeoMember ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember 2021-04-01 2022-03-31 9876543210 ecd:NonPeoNeoMember ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember 2021-04-01 2022-03-31 9876543210 ecd:NonPeoNeoMember ecd:AggtChngPnsnValInSummryCompstnTblForAplblYrMember 2020-04-01 2021-03-31 9876543210 ecd:NonPeoNeoMember ecd:PnsnAdjsSvcCstMember 2020-04-01 2021-03-31 9876543210 ecd:NonPeoNeoMember ecd:PnsnAdjsPrrSvcCstMember 2020-04-01 2021-03-31 9876543210 ecd:NonPeoNeoMember ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember 2020-04-01 2021-03-31 9876543210 ecd:NonPeoNeoMember ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember 2020-04-01 2021-03-31 9876543210 ecd:NonPeoNeoMember ecd:AggtChngPnsnValInSummryCompstnTblForAplblYrMember 2019-04-01 2020-03-31 9876543210 ecd:NonPeoNeoMember ecd:PnsnAdjsSvcCstMember 2019-04-01 2020-03-31 9876543210 ecd:NonPeoNeoMember ecd:PnsnAdjsPrrSvcCstMember 2019-04-01 2020-03-31 9876543210 ecd:NonPeoNeoMember ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember 2019-04-01 2020-03-31 9876543210 ecd:NonPeoNeoMember ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember 2019-04-01 2020-03-31 9876543210 ecd:PeoMember ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember 2021-04-01 2022-03-31 9876543210 ecd:PeoMember ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember 2021-04-01 2022-03-31 9876543210 ecd:PeoMember ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember 2021-04-01 2022-03-31 9876543210 ecd:PeoMember ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember 2021-04-01 2022-03-31 9876543210 ecd:PeoMember ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember 2021-04-01 2022-03-31 9876543210 ecd:PeoMember ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember 2021-04-01 2022-03-31 9876543210 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember 2020-04-01 2021-03-31 9876543210 ecd:PeoMember ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember 2020-04-01 2021-03-31 9876543210 ecd:PeoMember ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember 2020-04-01 2021-03-31 9876543210 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember 2020-04-01 2021-03-31 9876543210 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember 2020-04-01 2021-03-31 9876543210 ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember 2020-04-01 2021-03-31 9876543210 ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember 2020-04-01 2021-03-31 9876543210 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember 2019-04-01 2020-03-31 9876543210 ecd:PeoMember ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember 2019-04-01 2020-03-31 9876543210 ecd:PeoMember ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember 2019-04-01 2020-03-31 9876543210 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember 2019-04-01 2020-03-31 9876543210 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember 2019-04-01 2020-03-31 9876543210 ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember 2019-04-01 2020-03-31 9876543210 ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember 2019-04-01 2020-03-31 9876543210 ecd:NonPeoNeoMember ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember 2021-04-01 2022-03-31 9876543210 ecd:NonPeoNeoMember ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember 2021-04-01 2022-03-31 9876543210 ecd:NonPeoNeoMember ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember 2021-04-01 2022-03-31 9876543210 ecd:NonPeoNeoMember ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember 2021-04-01 2022-03-31 9876543210 ecd:NonPeoNeoMember ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember 2021-04-01 2022-03-31 9876543210 ecd:NonPeoNeoMember ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember 2021-04-01 2022-03-31 9876543210 ecd:NonPeoNeoMember ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember 2020-04-01 2021-03-31 9876543210 ecd:NonPeoNeoMember ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember 2020-04-01 2021-03-31 9876543210 ecd:NonPeoNeoMember ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember 2020-04-01 2021-03-31 9876543210 ecd:NonPeoNeoMember ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember 2020-04-01 2021-03-31 9876543210 ecd:NonPeoNeoMember ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember 2020-04-01 2021-03-31 9876543210 ecd:NonPeoNeoMember ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember 2020-04-01 2021-03-31 9876543210 ecd:NonPeoNeoMember ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember 2019-04-01 2020-03-31 9876543210 ecd:NonPeoNeoMember ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember 2019-04-01 2020-03-31 9876543210 ecd:NonPeoNeoMember ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember 2019-04-01 2020-03-31 9876543210 ecd:NonPeoNeoMember ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember 2019-04-01 2020-03-31 9876543210 ecd:NonPeoNeoMember ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember 2019-04-01 2020-03-31 9876543210 ecd:NonPeoNeoMember ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember 2019-04-01 2020-03-31 9876543210 2 2021-04-01 2022-03-31 9876543210 3 2021-04-01 2022-03-31 9876543210 4 2021-04-01 2022-03-31 9876543210 5 2021-04-01 2022-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:Y

 

THIS DOCUMENT IS A TECHNICAL ILLUSTRATION OF HOW CERTAIN DISCLOSURES IN SEC FILINGS ARE TO BE TAGGED. IT DOES NOT INDICATE WHICH PARTICULAR DISCLOSURES MUST BE INCLUDED AND/OR TAGGED IN COMMISSION FILINGS, AND IT DOES NOT CONSTITUTE LEGAL GUIDANCE OF ANY SORT.

 

SCHEDULE 14C

PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

PVP07 Specimen

Executive Compensation

Some text goes here. As described in the Compensation Discussion and Analysis beginning on page 99, our executive compensation programs aim to be competitive with our peers and aligned with our business strategy and corporate objectives. Our compensation philosophy emphasizes a pay for performance culture focused on the long-term interests of our shareholders. We believe that this alignment between executive compensation and shareholder interests will drive corporate performance over time. Additionally, the Company maintains strong governance and pay practices, including meaningful share ownership guidelines for directors and executive officers, clawback policies that apply to short-term cash awards and long-term equity awards, “double trigger” change in control benefits and performance of an annual compensation risk assessment by our Compensation Committee.

For purposes of the following Compensation Discussion and Analysis ("CD&A") and executive compensation disclosures, the individuals listed below are referred to collectively as our "Named Executive Officers." They are our President and Chief Executive Officer ("CEO"), our Executive Vice President, Chief Financial Officer as of the end of fiscal 2022 and our three other most highly compensated executive officers, based on fiscal 2022 compensation.

  Named Executive Officer Title   
  Fred W. Bock President and Chief Executive Officer  
  Audie K. Gale (1) Executive Vice President, Chief Financial Officer  
  Florence A. Hood Executive Vice President, General Counsel  
  Robin M. Murphy Executive Vice President, Global Manufacturing and Supply Chain  
  Nathan L. Bowie President, Global Hospital  

(1) Mr. Gale retired as Chief Financial Officer after the completion of fiscal 2022 and was succeeded by James N. Tell in April 2022.

 

Pay Versus Performance 

(dollars in thousands, except as indicated)

                                 
                    Value of Initial Fixed $100 Investment based on:         Company Selected Measure:  
Year      Summary Comp. Table Total for PEO     Comp. Actually Paid to PEO     Average Summary Comp. Table Total for non-PEO Named Executive Officers    

Average Comp. Actually Paid to non-PEO Named Executive Officers

    Total Share holder Return      Peer Group Total Share holder Return     Net Income from continuing operations, including portion attributable to noncontrolling interest     Relative Total Share holder Return (rTSR) Percentile   
 2022    8,702   8,102  (1)  6,702  (2)   6,107  (3)  44.50    159.59  (4) 43,375      12  (5)
 2021     8,625     8,043      6,625      5,683      77.07      135.39      79,469      5   
 2020     9,398 (6)   8,816      7,398      6,816      145.79      117.45      76,526      72   
 2019     11,283      11,283      2,297      2,297      208.28      104.79      84,175      53   
 2018     18,121      18,121      4,466      4,466      186.30      101.00      140,267      92   

 

   
 (1) As adjusted per $3.1 addition and $2.5 deduction because of various and sundry reasons including a 7% solution and 98th percentile with an estimated count of 909, computed as the double log mean ratio of net income to third moment of value at risk.
(2) For fiscal years 2018 through 2022, Fred W. Bock is included as the PEO, and Audie K. Gale, Florence A. Hood, Robin M. Murphy, and Nathan L. Bowie are included as other NEOs.
(3) Includes the effect of deductions of $1m for Messrs. Gale and Murphy, respectively, and $860,000 for Ms. Hood for miscellaneous reasons and additions of $250,000 for Ms. Hood and Mr. Bowie, and $300,000 for Mr. Murphy also for various reasons.
(4)

Peer group companies currently include VAF, Inc., KKW Medical, Inc., EQE Laboratories, Inc., APP Corp., EKQ Corporation, OUM Medical Corp., HIB, Inc., TZC Medical, Inc., WYP Medical, Inc., HFK Corporation, QIZ LifeSciences, LMK Corporation, OLY, Inc., TKV, Inc., WPS Inc., NWQ PLC, and CDG Pharmaceutical Services, Inc., and ZYZ AG.

(5) Relative total shareholder return (rTSR) is defined as the percentile of the company’s three-year cumulative TSR within the peer group.
Year SCT Total for PEO ($) Less: Pension Value Reported in SCT ($) Plus: Pension Benefits Service cost ($) Plus: Pension Adjustments Prior Service Cost ($) Less: Reported Grant Date Fair Value of Equity Awards in SCT ($) Plus: Equity Award Adjustments Excluding Value Reported in SCT ($) Compensation Actually Paid to PEO ($)
2022 8,702 (100) 40 15 (3,100) 2,545 8,102 
2021 8,625 (120) 35 30 (3,053) 2,526 8,043
2020 9,398 (60) 30 40 (2,897) 2,305 8,816

 

 

Year Average SCT Total for Non-PEO NEOs ($) Less: Average Pension Value Reported in SCT ($) Plus: Average Pension Benefits Service cost ($) Plus: Average Pension Adjustments Prior Service Cost ($) Less: Average Reported Grant Date Fair Value of Equity Awards in SCT ($) Plus: Average Equity Award Adjustments Excluding Value Reported in SCT ($) Average Compensation Actually Paid to Non-PEO NEO ($)
2022 6,702 (80) 30 10 (2,100) 1,545 6,107
2021 6,625 (100) 25 10 (2,403) 1,526 5,683
2020 7,398 (40) 20 30 (1,897) 1,305 6,816

 

The amounts in the Equity Award Adjustments Excluding Value Reported in SCT in the tables above are derived from the amounts set forth in the following tables. The amounts shown below for non-PEO NEOs for each year represents an average of all Non-PEO NEOs.

  Year End Fair Value of Equity Awards Granted In Covered Year Outstanding And Unvested ($) Change In Fair Value of Outstanding And Unvested Equity Awards Granted In Prior Years ($) Vesting Date Fair Value of Equity Awards Granted And Vested In Covered Year ($) Change In Fair Value as of Vesting Date of Prior Year Equity Awards Vested In Covered Year ($) Fair Value as of Prior Year End of Equity Awards Granted In Prior Years That Failed To Meet Vesting Conditions During Covered Year ($) Dividends or Other Earnings Paid on Equity Awards Not Otherwise Reflected In Total Compensation For The Covered Year ($) Total Equity Award Adjustments Excluding Value Reported in SCT ($)
PEO 2022 1,500 600 500 245 (300) 100 2,545
PEO 2021 1,400 500 400 276 (250) 200 2,526
PEO 2020 1,300 400 300 205 (200) 300 2,305

 

  Year End Fair Value of Equity Awards Granted In Covered Year Outstanding And Unvested ($) Change In Fair Value of Outstanding And Unvested Equity Awards Granted In Prior Years ($) Vesting Date Fair Value of Equity Awards Granted And Vested In Covered Year ($) Change In Fair Value as of Vesting Date of Prior Year Equity Awards Vested In Covered Year ($) Fair Value as of Prior Year End of Equity Awards Granted In Prior Years That Failed To Meet Vesting Conditions During Covered Year ($) Dividends or Other Earnings Paid on Equity Awards Not Otherwise Reflected In Total Compensation For The Covered Year ($) Total Equity Award Adjustments Excluding Value Reported in SCT ($)
Non-PEO NEOS 2022 1,000 500 300 205 (550) 90 1,545
Non-PEO NEOS 2021 900 400 200 236 (400) 190 1,526
Non-PEO NEOS 2020 800 300 200 265 (540) 280 1,305

This is a clear description (graphically, narratively, or both graphically and narratively)

little

of the relationships between PEO and non-PEO compensation actually paid vs Total Shareholder Return.

This is a clear description (graphically, narratively, or both graphically and narratively) of the relationships

little

between PEO and Non-PEO compensation actually paid vs Net Income.

This is a clear description (graphically,

little

narratively, or both graphically and narratively) of the relationships between PEO and non-PEO compensation actually paid vs Relative Total Shareholder Return (rTSR).

This is a clear description (graphically, narratively, or both graphically and narratively) of the relationships between Company Total Shareholder Return vs Peer Group Total Shareholder Return.

little

 

 Five Most Important Company Performance Measures for Determining NEO Compensation  
  Relative Total Shareholder Return (rTSR) 
  Adjusted Revenue 
  Adjusted EPS  
  Hospital Business Unit Revenue  
  Adjusted Operating Income  

 

Additional paragraphs of rule 402(v) disclosures relating to executive pay as compared to performance.

Additional paragraphs of rule 402(v) disclosures relating to executive pay as compared to performance.